BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Nawfal R Hussein. Sustained Virological Response After Six Weeks Treatment with a Sofosbuvir-Containing Regimen in a Patient Infected with Hepatitis C Virus Genotype 4: A Case ReportInternational Journal of Infection 2016; 4(3) doi: 10.5812/iji.41216
2
Rafael Gonzalez Alonso, Maria Fernanda Gomez, Mary Alice O’Dowd. Geriatric Gastroenterology2020; : 1 doi: 10.1007/978-3-319-90761-1_92-1
3
Georg Dultz, Tobias Müller, Jörg Petersen, Stefan Mauss, Tim Zimmermann, Marion Muche, Karl-Georg Simon, Thomas Berg, Stefan Zeuzem, Dietrich Hüppe, Klaus Böker, Heiner Wedemeyer, Tania M. Welzel. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C RegistryDrugs & Aging 2018; 35(9): 843 doi: 10.1007/s40266-018-0572-0
4
Alessandro Federico, Giuseppe Gerardo Caprio, Anna Maria Dalise, Michelangela Barbieri, Marcello Dallio, Carmelina Loguercio, Giuseppe Paolisso, Maria Rosaria Rizzo. Cirrhosis and frailty assessment in elderly patientsMedicine 2020; 99(2): e18501 doi: 10.1097/MD.0000000000018501
5
Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José V Fernández-Montero, Isabella Esposito, Laura Benítez-Gutiérrez, José M Peña, Pablo Barreiro. New hepatitis C therapies for special patient populationsExpert Opinion on Pharmacotherapy 2016; 17(2): 217 doi: 10.1517/14656566.2016.1112790
6
Tamer Elbaz, Mahmoud Abdo, Heba Omar, Essam A. Hassan, Amr M. Zaghloul, Mohamed Abdel‐Samiee, Ahmed Moustafa, Abdallah Qawzae, Mostafa Gamil, Gamal Esmat. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infectionJournal of Medical Virology 2019; 91(2): 272 doi: 10.1002/jmv.25287
7
Stephanie E Perrett, Amy Plimmer, Ananda Giri Shankar, Noel Craine. Prevalence of HCV in prisons in Wales, UK and the impact of moving to opt-out HCV testingJournal of Public Health 2020; 42(2): 423 doi: 10.1093/pubmed/fdaa022
8
Antonio De Vincentis, Luisa Costanzo, Umberto Vespasiani-Gentilucci, Antonio Picardi, Stefania Bandinelli, Luigi Ferrucci, Raffaele Antonelli Incalzi, Claudio Pedone. Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older peopleDigestive and Liver Disease 2019; 51(9): 1330 doi: 10.1016/j.dld.2019.01.017
9
Chiara Mazzarelli, Aisling Considine, Kate Childs, Ivana Carey, Matteo Angelo Manini, Abid Suddle, Geoffrey Dusheiko, Kosh Agarwal, Mary D. Cannon. Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older AdultsJournal of the American Geriatrics Society 2018; 66(7): 1339 doi: 10.1111/jgs.15392
10
J. Vermehren, K.-H. Peiffer, C. Welsch, G. Grammatikos, M.-W. Welker, N. Weiler, S. Zeuzem, T. M. Welzel, C. Sarrazin. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infectionAlimentary Pharmacology & Therapeutics 2016; 44(8): 856 doi: 10.1111/apt.13769
11
Daniel Esteban Pino Marín, Pedro Amariles, Jaime Alberto Peláez Alvárez, Gloria Priscilla Alvárez Osorio, Juliana González Ceballos. Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C, revisión estructurada (actualización 2015 – 2017)Revista Colombiana de Gastroenterología 2019; 34(2): 159 doi: 10.22516/25007440.252
12
Claudia Fabrizio, Annalisa Saracino, Luigia Scudeller, Eugenio Milano, Raffaele Dell’Acqua, Giuseppe Bruno, Sergio Lo Caputo, Laura Monno, Michele Milella, Gioacchino Angarano. The elderly and direct antiviral agents: Constraint or challenge?Digestive and Liver Disease 2017; 49(9): 1036 doi: 10.1016/j.dld.2017.05.019
13
Nawfal R Hussein. Sofosbuvir and Ribavirin to Treat Hepatitis C Virus Genotype 4 Infection in a 65-Year-Old Patient With Diabetes and Low Platelet: A Case ReportInternational Journal of Infection 2016; 3(4) doi: 10.17795/iji-36642
14
Chung-Feng Huang, Ming-Lung Yu. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developmentsExpert Opinion on Pharmacotherapy 2017; 18(17): 1867 doi: 10.1080/14656566.2017.1400010
15
Nawfal R Hussein. Sustained Virological Response After Six Weeks Treatment with a Sofosbuvir-Containing Regimen in a Patient Infected with Hepatitis C Virus Genotype 4: A Case ReportInternational Journal of Infection 2016; (Inpress) doi: 10.17795/iji-41216
16
Daniel J. Ruzicka, Jumpei Tetsuka, Go Fujimoto, Tatsuya Kanto. Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016BMC Infectious Diseases 2018; 18(1) doi: 10.1186/s12879-018-3148-z
17
Ugo Fedeli, Elena Schievano. Mortality Waves Related to Hepatitis C Virus Infection: Multiple Causes of Death Data From the United States and Northern Italy ComparedClinical Infectious Diseases 2016; 63(6): 849 doi: 10.1093/cid/ciw421
18
Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, Tsai-Yuan Hsieh, Yi-Hsiang Huang, Wei-Wen Su, Pin-Nan Cheng, Chih-Lin Lin, Ching-Chu Lo, Chi-Yi Chen, Jyh-Jou Chen, Qian Ma, Craig Brooks-Rooney, Jia-Horng Kao. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE studyJournal of the Formosan Medical Association 2019; 118(6): 1014 doi: 10.1016/j.jfma.2018.10.020
19
F. Giudici, B. Bertisch, F. Negro, G. Stirnimann, B. Müllhaupt, D. Moradpour, A. Cerny, O. Keiser. Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approachJournal of Viral Hepatitis 2016; 23(9): 697 doi: 10.1111/jvh.12535
20
Alexandre Pariente, Jean-Pierre Arpurt, Andre-Jean Remy, Isabelle Rosa-Hezode, Xavier Causse, Frederic Heluwaert, Gilles Macaigne, Jean Henrion, Christophe Renou, Matthieu Schnee, Hatem Salloum, Severine Hommel, Christophe Pilette, Ramuntxo Arotcarena, Georges Barjonet, Hortensia Lison, Frangois Bourhis, Vincent Jouannaud, Arnaud Pauwels, Yann Le-Bricquir, Edmond Geagea, Bertrand Condat, Marie-Pierre Ripault, David Zanditenas, Stephanie de Montigny-Lenhardt, Helene Labadie, Bertrand Tissot, Eric Maringe, Jean-Frangois Cadranel, Herve Hagege, Bruno Lesgourgues. Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting AntiviralsAnnals of Hepatology 2019; 18(1): 193 doi: 10.5604/01.3001.0012.7912
21
Ugo Fedeli, Enrico Grande, Francesco Grippo, Luisa Frova. Mortality associated with hepatitis C and hepatitis B virus infection: A nationwide study on multiple causes of death dataWorld Journal of Gastroenterology 2017; 23(10): 1866-1871 doi: 10.3748/wjg.v23.i10.1866
22
K. Tajiri, Y. Shimizu. Liver Pathophysiology2017; : 331 doi: 10.1016/B978-0-12-804274-8.00026-6
23
Almurdi ., Ellyza Nasrul, Saptino Miro. Level of Interferon-gamma and Interleukin-12 in Several Genotypes of HCV InfectionsJournal of Medical Sciences 2018; 18(4): 180 doi: 10.3923/jms.2018.180.185
24
Iria Rodríguez-Osorio, Alvaro Mena, Héctor Meijide, Luis Morano, Manuel Delgado, Purificación Cid, Luis Margusino, José Domingo Pedreira, Ángeles Castro, Ferruccio Bonino. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antiviralsPLOS ONE 2019; 14(6): e0217052 doi: 10.1371/journal.pone.0217052
25
Charles D. Ciccone. Guccione's Geriatric Physical Therapy2020; : 102 doi: 10.1016/B978-0-323-60912-8.00006-3
26
Victor Virlogeux, Laure Choupeaux, Pierre Pradat, Marianne Maynard, François Bailly, Caroline Scholtès, Marie-Claude Gagnieu, Fabien Zoulim. Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decayDigestive and Liver Disease 2016; 48(11): 1351 doi: 10.1016/j.dld.2016.07.014
27
Marcus M. Mücke, Eva Herrmann, Victoria T. Mücke, Christiana Graf, Stefan Zeuzem, Johannes Vermehren. Efficacy and safety of direct‐acting antivirals for hepatitis C in the elderly: A systematic review and meta‐analysisLiver International 2019; 39(9): 1652 doi: 10.1111/liv.14126
28
Mubeen Khan Mohammed Abdul, Heather S. Snyder, Mythili Chunduru, Susan M.K. Lee, Sanjaya K. Satapathy. Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to CureCurrent Treatment Options in Infectious Diseases 2020;  doi: 10.1007/s40506-020-00231-8
29
Loreta A. Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, Anna Linda Zignego, Monica Monti, Andrea Gori, Alessandro Soria, Giovanni Raimondo, Roberto Filomia, Alfredo Di Leo, Andrea Iannone, Marco Massari, Romina Corsini, Roberto Gulminetti, Alberto Gatti Comini, Pierluigi Toniutto, Denis Dissegna, Francesco Paolo Russo, Alberto Zanetto, Maria Grazia Rumi, Giuseppina Brancaccio, Elena Danieli, Maurizia Rossana Brunetto, Liliana Elena Weimer, Maria Giovanna Quaranta, Stefano Vella, Massimo Puoti, Ravi Jhaveri. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyPLOS ONE 2017; 12(2): e0172159 doi: 10.1371/journal.pone.0172159
30
Marilena Durazzo, Elena Ponzo, Silvia Bonetto, Sharmila Fagoonee, Rinaldo Pellicano. Liver diseases in the elderlyMinerva Medica 2019; 110(1) doi: 10.23736/S0026-4806.18.05858-5